Acquisitions and License Agreements (Narrative) (Details) (USD $)	3 Months Ended									12 Months Ended			3 Months Ended	0 Months Ended				0 Months Ended		9 Months Ended	12 Months Ended		0 Months Ended			3 Months Ended	12 Months Ended					60 Months Ended	1 Months Ended	12 Months Ended		60 Months Ended	12 Months Ended			60 Months Ended		0 Months Ended					1 Months Ended		12 Months Ended
	Sep. 26, 2014	Jun. 27, 2014	Mar. 28, 2014	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013		Mar. 29, 2013	Dec. 28, 2012	Sep. 26, 2014	Sep. 27, 2013	Sep. 28, 2012	Sep. 26, 2014 Nuvo	Aug. 14, 2014 Questcor Pharmaceuticals, Inc.	Apr. 05, 2014 Questcor Pharmaceuticals, Inc.	Sep. 26, 2014 Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 Questcor Pharmaceuticals, Inc.	Mar. 19, 2014 Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 CNS Therapeutics, Inc.	Jun. 27, 2014 Acthar Questcor Pharmaceuticals, Inc. pharmacy_indications	Sep. 27, 2013 Intrathecal	Sep. 26, 2014 Bristol-Myers Squibb Licensing Agreements	Mar. 19, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc. In-process research and development	Sep. 28, 2012 Specialty Pharmaceuticals Roxicodone	Sep. 26, 2014 Specialty Pharmaceuticals Roxicodone	Sep. 27, 2013 Specialty Pharmaceuticals Roxicodone	Sep. 26, 2014 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 28, 2012 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Exalgo Licensing Agreements	Jul. 31, 2014 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 26, 2014 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 26, 2014 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 28, 2012 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 27, 2013 Finite-Lived Intangible Assets Specialty Pharmaceuticals Exalgo Licensing Agreements	Aug. 14, 2014 Completed Technology Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 Customer relationships Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 Trademarks Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 In-process research and development Questcor Pharmaceuticals, Inc.	Oct. 01, 2012 In-process research and development Specialty Pharmaceuticals CNS Therapeutics, Inc.	Jan. 31, 2014 Royalty rights Exalgo	Mar. 19, 2014 Term loan due March 2021 Secured Debt	Sep. 26, 2014 Term loan due March 2021 Term Loan
Business Acquisition [Line Items]
Total consideration														$ 5,915,300,000				$ 1,329,200,000					$ 1,300,000,000	$ 98,600,000
Cash consideration per share															30								14
Amount of company shares shareholders will receive, per share															0.897
Issuance of common stock to acquire business														57,000,000
Issuance of senior unsecured notes to acquire business														900,000,000
Issuance of senior secured term loan facility to acquire business														700,000,000
Cash used to acquire business														150,000,000
Number of indications that are approved for treatment																				19
Debt instrument, face amount																																																1,300,000,000.0
Total consideration, net of cash														5,470,200,000				1,286,000,000						95,000,000
Cash payment, net of cash acquired										2,793,800,000	88,100,000	13,200,000												88,100,000
Plus: cash assumed in acquisition																	445,100,000	43,200,000						3,600,000
Contingent consideration																	0	0	6,900,000					6,900,000
Contingent consideration, potential maximum																215,000,000.0			9,000,000.0					9,000,000
Cash flow discount rate																		13.00%							35.00%																	14.50%	10.00%	10.00%	16.00%
Estimated cost to complete in-process research																																														18,000,000
Line of credit facility, interest rate during period																																																	3.50%
Net sales	789,300,000	653,100,000	557,800,000	540,200,000	545,200,000	570,000,000	[1]	585,300,000	504,000,000	2,540,400,000	2,204,500,000	2,056,200,000									29,200,000						13,100,000	8,400,000
Payment to acquire intangible assets																										13,200,000
Contingent payment, maximum additional amount																						25,000,000							73,000,000					64,000,000			120,000,000
Royalties paid																						13,200,000							22,000,000	24,000,000	16,100,000						4,300,000	3,900,000	7,500,000
Milestone payments																																65,000,000	5,000,000	10,000,000	5,000,000	22,000,000				15,000,000	55,000,000
Finite-lived intangible assets acquired																																															7,200,000
Non-cash impairment charges										$ 381,200,000	$ 0	$ 0	$ 11,100,000

[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.